<DOC>
	<DOCNO>NCT01664143</DOCNO>
	<brief_summary>This single-center , randomize , double-blind , placebo-controlled study evaluate safety , pharmacokinetics pharmacodynamics RO5508887 healthy volunteer . Volunteers receive multiple-ascending dos RO5508887 match placebo . The anticipated time study treatment 14 day .</brief_summary>
	<brief_title>A Single-Center Study RO5508887 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Adult healthy volunteer , &gt; /=18 year age Body mass index ( BMI ) 18 30 kg/m2 inclusive Use adequate contraception method surgically sterile Evidence active chronic disease Regular consumption drug abuse Regular smoker ( &gt; 5 cigarette per day ) Infection human immunodeficiency virus ( HIV ) , hepatitis B ( HBV ) hepatitis C ( HCV ) History significant allergic reaction Abnormal blood pressure Clinical significant abnormality ( e.g. , cardiovascular , laboratory value )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>